1. Home
  2. ARVN vs EH Comparison

ARVN vs EH Comparison

Compare ARVN & EH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$7.57

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Logo EHang Holdings Limited ADS

EH

EHang Holdings Limited ADS

HOLD

Current Price

$7.12

Market Cap

679.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARVN
EH
Founded
2015
2014
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Military/Government/Technical
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
658.2M
679.5M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
ARVN
EH
Price
$7.57
$7.12
Analyst Decision
Buy
Strong Buy
Analyst Count
19
3
Target Price
$15.05
$22.47
AVG Volume (30 Days)
694.3K
1.4M
Earning Date
05-04-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
58.84
N/A
EPS
N/A
N/A
Revenue
$262,600,000.00
N/A
Revenue This Year
N/A
$33.23
Revenue Next Year
N/A
$73.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.06
$6.50
52 Week High
$14.22
$20.44

Technical Indicators

Market Signals
Indicator
ARVN
EH
Relative Strength Index (RSI) 37.96 37.09
Support Level $7.35 N/A
Resistance Level $10.18 $10.58
Average True Range (ATR) 0.42 0.68
MACD 0.05 -0.16
Stochastic Oscillator 31.43 15.17

Price Performance

Historical Comparison
ARVN
EH

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About EH EHang Holdings Limited ADS

EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.

Share on Social Networks: